Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $35.5 million.

  • Autolus Therapeutics' Cash from Investing Activities rose 47070.6% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$311.7 million, marking a year-over-year decrease of 240541.8%. This contributed to the annual value of -$394.6 million for FY2024, which is 349140.72% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Cash from Investing Activities of $35.5 million as of Q3 2025, which was up 47070.6% from $95.9 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Cash from Investing Activities peaked at $95.9 million during Q2 2025, and registered a low of -$383.6 million during Q4 2024.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$1.6 million (2021), whereas its average is -$18.6 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Cash from Investing Activities plummeted by 2587081.92% in 2024, and later skyrocketed by 1150487.51% in 2025.
  • Autolus Therapeutics' Cash from Investing Activities (Quarter) stood at -$1.6 million in 2021, then surged by 60.06% to -$633000.0 in 2022, then plummeted by 133.33% to -$1.5 million in 2023, then tumbled by 25870.82% to -$383.6 million in 2024, then surged by 109.27% to $35.5 million in 2025.
  • Its Cash from Investing Activities was $35.5 million in Q3 2025, compared to $95.9 million in Q2 2025 and -$59.5 million in Q1 2025.